▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #19 by analyst upside · 2026-06-27
GOSS
Gossamer Bio, Inc.
Healthcare · Market Cap $77M · P/E 0x
ANALYST PRICE TARGET
+2356.1%
implied upside to consensus target
Current Price $0.16
Consensus Target $3.86
Bull Target $15.0
Bear Target $0.28
Analysts Covering 5
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
1
Hold
3
Sell
0
52-Week Low $0.14
52-Week High $3.87
YTD Return -94.5%
FUNDAMENTALS
Market Cap $77M
P/E Ratio (TTM) N/A
Forward P/E -1.6x
EPS (TTM) $-0.77
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $56M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.14
52-Week High $3.87
Current Price $0.16
Bear Target $0.28
Bull Target $15.0
● Now $0.16 ● Target $3.86
TRADING DATA
Avg Volume 11.7M
YTD Return -94.5%
Analyst Count 5
Consensus Buy
Upside to Target +2356.1%
Last Updated 2026-06-27

ANALYST SUMMARY

Gossamer Bio, Inc. (GOSS) is currently trading at $0.16 with a Wall Street consensus price target of $3.86, implying potential upside of 2356.1% over the next 12 months. 5 analysts currently cover GOSS, with a consensus rating of Buy — 40% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $15.0, while the most cautious has a target of $0.28.

GOSS operates in the Healthcare sector with a market capitalisation of $77M. The stock is down 94.5% year-to-date and is currently trading near the lower end of its 52-week range of $0.14 – $3.87.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

OSRH +2894.0%
OSR Health, Inc.
$12M · P/E 11.1x · Hold
PSTV +757.1%
Plus Therapeutics, Inc.
$29M · P/E 0.2x · Buy
DWTX +748.5%
Dogwood Therapeutics, Inc.
$55M · P/E 1.4x · Strong Buy
ETST +566.7%
Earth Science Tech, Inc.
$43M · P/E 15.0x · Hold
VXRT +488.2%
Vaxart, Inc.
$123M · P/E 3.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for GOSS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-05-26 31% win rate (48 calls)
Barclays — Reiterated
Underweight → Underweight 2026-05-19 Building track record
Cantor Fitzgerald ↓ Downgrade
Overweight → Neutral 2026-03-23 40% win rate (10 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-06 31% win rate (48 calls)
Oppenheimer — Reiterated
Outperform → Outperform 2026-03-05 14% win rate (7 calls)
Wedbush ↓ Downgrade
Outperform → Neutral 2026-02-24 Building track record
Barclays ↓ Downgrade
Overweight → Underweight 2026-02-24 Building track record
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2026-02-24 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →